SLS
NASDAQ · Biotechnology
Sellas Life Sciences Group I
$9.03
-0.11 (-1.20%)
SLS News12 articles
SELLAS: Cash Buffer vs. $150M ATM Overhang
SELLAS has a 4.2-year cash runway, but its $150M ATM facility still looms. Clinical readouts from REGAL and SLS009 will determine the timing and cost of future dilution.
SELLAS Life Sciences Shares Plunge 14% Ahead of Key Clinical Data
SELLAS Life Sciences (SLS) fell 14% on Friday with no disclosed bad news, as traders de-risk ahead of binary clinical milestones. The stock closed at $11.545.
SELLAS Surges 18.9% as REGAL Trial Nears Pivotal Final Analysis
SELLAS Life Sciences (SLS) shares surged 18.9% over the past week, driven by anticipation of the REGAL trial's final analysis. Market value stands at $3.12 billion, with pipeline valued at $2.98 billion.
SELLAS Surges 15% as Investors Bet Big on AML Trial Results
SELLAS shares climbed 15.37% to $15.46, lifting market cap to $3.12B. Cash covers only 4.4%, with pipeline value hinging on AML trial results.
SELLAS Life Sciences Shares Slide 3.9% as Dilution Concerns Weigh on Valuation
SELLAS Life Sciences shares dropped 3.9% on Monday as the latest share count of 196.6 million suggests a $2.14 billion market cap, 14% above the live feed. The biotech awaits final REGAL trial data.
SELLAS Life Sciences Stock Tumbles 14% on REGAL Trial Uncertainty
SELLAS Life Sciences shares dropped 14% on Friday amid investor caution over the REGAL Phase 3 trial timeline, testing the company's $2.2 billion market cap.
SELLAS Life Sciences Stock Jumps 12% Ahead of Key Trial Results
SELLAS Life Sciences rose 12.3% on Friday, closing at $13.19, with a market cap discrepancy of $319 million ahead of REGAL trial results.
SELLAS Life Sciences Surges 12% as Equity Value Soars $1.6B
SELLAS Life Sciences shares climbed 12.3% to $13.19, lifting estimated equity value by $1.62 billion since May. The REGAL trial's 80th event is pending.
SELLAS Life Sciences Soars on Heavy Short Interest Ahead of AML Trial Results
SELLAS Life Sciences (SLS) surged 6.3% to $11.19 as short interest climbed to 32.65% of float and trading volume doubled. The company amended executive severance terms and disclosed 78 of 80 events reached in its Phase 3 AML trial.
SELLAS Life Sciences Soars on Executive Severance Update
SELLAS Life Sciences (SLS) surged 12.6% to $10.33 on heavy volume after an 8-K filing revealed changes to executive severance terms. The stock's implied equity value reached $2.03 billion.
SELLAS Shares Surge as AML Trial Nears Final Data Trigger
SELLAS Life Sciences shares climbed 4.1% to $7.59 on Tuesday after the CEO disclosed the REGAL trial is nearing the 80-event threshold for final analysis.
SELLAS Stock Surges as REGAL Trial Nears Final Analysis
SELLAS Life Sciences shares rose after hours as its REGAL leukemia trial recorded 78 of 80 events needed for final analysis. The company reported a Q1 net loss of $8.4 million but has $107.1 million in cash.